2025-06-12-花旗集团-皇家制药（RPRX）_皇家制药（RPRX.N）_首席执行官_首席财务官电话会议系列要点_业务发展能力和创造股东价值仍然是首要任务_10页_231kb

报告摘要

Business Development Focus: Royalty Pharma prioritizes business development and generating shareholder value, remaining relatively shielded from policy changes. This aptitude allows the company to secure successful royalty deals.
Chinese Market Potential: The company is exploring partnerships with Chinese biotechs, citing faster product progression in China and the difficulty Chinese firms face in obtaining capital, which could benefit Royalty Pharma's synthetic royalty deals.
Investment Process: Enhanced due diligence processes enable value creation, with a bias toward large TAM opportunities, though the company remains open to orphan indications.
Citi's Recommendation: Maintain "Buy" rating with a target price of $40, expecting a 17.5% share price return and 19.9% total return.
Upcoming Events: An investor day on September 11 is anticipated, where the company may provide long-term guidance and updates on assets like Servier's Voranigo.

Target Price: $40 per share.
Methodology: Sum-of-the-parts DCF model, discounting cash flows through 2030 at a WACC of 6% and a terminal growth rate of 1.2%.

Upside Risks: Higher IRRs on new investments, increased sales of existing products (e.g., Cystic Fibrosis, Imbruvica), or more significant investments.
Downside Risks: Personnel turnover affecting due diligence quality, lower returns on new investments, increased competition for royalty assets, or changes in tax rules reducing profits.